David A. Siegel Vanda Pharmaceuticals Inc. Transaction History

Two Sigma Advisers, LP

$41.3 Billion
Q3 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Vanda Pharmaceuticals Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 140,600 shares of VNDA stock, worth $688,940. This represents 0.0% of its overall portfolio holdings.

Number of Shares

140,600

Previous 214,100 34.33%

Holding current value

$688,940

Previous $1.21 Million 45.49%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$4.61 - $6.34 $338,835 - $465,990	-73,500 Reduced 34.33%	140,600 $659,000
Q2 2024 Aug 14, 2024	SELL	$3.91 - $6.5 $1.92 Million - $3.18 Million	-489,800 Reduced 69.58%	214,100 $1.21 Million
Q1 2024 May 15, 2024	SELL	$3.47 - $4.61 $633,622 - $841,786	-182,600 Reduced 20.6%	703,900 $2.89 Million
Q4 2023 Feb 14, 2024	BUY	$3.38 - $4.58 $399,516 - $541,356	118,200 Added 15.38%	886,500 $3.74 Million
Q3 2023 Nov 14, 2023	BUY	$4.28 - $6.57 $610,328 - $936,882	142,600 Added 22.79%	768,300 $3.32 Million
Q2 2023 Aug 14, 2023	BUY	$5.9 - $6.95 $284,970 - $335,685	48,300 Added 8.37%	625,700 $4.12 Million
Q1 2023 May 15, 2023	BUY	$6.18 - $7.99 $766,320 - $990,760	124,000 Added 27.35%	577,400 $3.92 Million
Q4 2022 Feb 14, 2023	BUY	$6.87 - $10.96 $107,172 - $170,976	15,600 Added 3.56%	453,400 $3.35 Million
Q3 2022 Nov 14, 2022	SELL	$9.44 - $11.76 $1.4 Million - $1.74 Million	-147,900 Reduced 25.25%	437,800 $4.33 Million
Q2 2022 Aug 15, 2022	SELL	$9.31 - $11.84 $2,793 - $3,552	-300 Reduced 0.05%	585,700 $6.38 Million
Q1 2022 May 16, 2022	BUY	$10.84 - $16.55 $418,424 - $638,830	38,600 Added 7.05%	586,000 $6.63 Million
Q4 2021 Feb 14, 2022	BUY	$15.69 - $21.14 $2.5 Million - $3.36 Million	159,100 Added 40.97%	547,400 $8.59 Million
Q3 2021 Nov 15, 2021	SELL	$15.35 - $21.27 $319,280 - $442,416	-20,800 Reduced 5.08%	388,300 $6.66 Million
Q2 2021 Aug 16, 2021	BUY	$15.71 - $21.51 $1.32 Million - $1.8 Million	83,800 Added 25.76%	409,100 $8.8 Million
Q1 2021 May 17, 2021	BUY	$13.42 - $20.28 $747,494 - $1.13 Million	55,700 Added 20.66%	325,300 $4.89 Million
Q4 2020 Feb 16, 2021	SELL	$9.77 - $13.81 $412,294 - $582,782	-42,200 Reduced 13.53%	269,600 $3.54 Million
Q3 2020 Nov 16, 2020	SELL	$9.32 - $12.02 $1.21 Million - $1.56 Million	-129,800 Reduced 29.39%	311,800 $3.01 Million
Q2 2020 Aug 14, 2020	BUY	$9.66 - $12.02 $235,704 - $293,288	24,400 Added 5.85%	441,600 $5.05 Million
Q1 2020 May 15, 2020	BUY	$7.5 - $16.8 $263,250 - $589,680	35,100 Added 9.19%	417,200 $4.32 Million
Q4 2019 Feb 14, 2020	BUY	$12.38 - $17.47 $51,996 - $73,374	4,200 Added 1.11%	382,100 $6.27 Million
Q3 2019 Nov 14, 2019	SELL	$12.27 - $15.79 $517,794 - $666,338	-42,200 Reduced 10.05%	377,900 $5.02 Million
Q2 2019 Aug 14, 2019	BUY	$13.37 - $18.85 $1.59 Million - $2.24 Million	118,600 Added 39.34%	420,100 $5.92 Million
Q1 2019 May 15, 2019	BUY	$17.59 - $31.05 $1.28 Million - $2.26 Million	72,800 Added 31.83%	301,500 $5.55 Million
Q4 2018 Feb 14, 2019	SELL	$18.97 - $31.47 $821,401 - $1.36 Million	-43,300 Reduced 15.92%	228,700 $5.98 Million
Q3 2018 Nov 14, 2018	SELL	$18.25 - $23.0 $512,825 - $646,300	-28,100 Reduced 9.36%	272,000 $6.24 Million
Q2 2018 Aug 14, 2018	BUY	$13.95 - $19.15 $2.27 Million - $3.11 Million	162,600 Added 118.25%	300,100 $5.72 Million
Q1 2018 May 15, 2018	BUY	$14.05 - $20.2 $425,715 - $612,060	30,300 Added 28.26%	137,500 $2.32 Million
Q4 2017 Feb 14, 2018	SELL	$12.85 - $18.1 $566,685 - $798,210	-44,100 Reduced 29.15%	107,200 $1.63 Million
Q3 2017 Nov 14, 2017	BUY	$15.4 - $18.85 $2.33 Million - $2.85 Million	151,300	151,300 $2.71 Million

Others Institutions Holding VNDA

# of Institutions

161

Shares Held

45.2M

Call Options Held

165K

Put Options Held

33.6K

View Full List

About Vanda Pharmaceuticals Inc.

Ticker VNDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,561,500
Market Cap $277M
Description
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under developme...

More about VNDA

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account